A MULTIPLE-DOSE, COMPARATIVE BIOAVAILABILITY STUDY OF TWO FORMULATIONS OF QUETIAPINE 400 MG PROLONGED RELEASE TABLETS UNDER FASTING CONDITIONS IN SUBJECTS WITH PRIMARY PSYCHOTIC AND/OR BIPOLAR DISORDER

Registry ID

2013-3193

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

TEVA CANADA LIMITED

Start date

2013-04-14

Last update

2013-04-04

Conditions

• PSYCHOTIC DISORDER
• BIPOLAR DEPRESSION

Related clinical trials

• CANNABIDIOL ADJUNCTIVE THERAPY FOR ACUTE BIPOLAR DEPRESSION: A RANDOMIZED DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL
• NEUROBIOLOGICAL EFFECTS OF PSILOCYBIN IN TREATMENT RESISTANT BIPOLAR DEPRESSION: AN EMOTIONAL-PROCESSING FMRI PILOT STUDY
• MAINTENANCE KETAMINE INFUSIONS FOR TREATMENT-RESISTANT BIPOLAR DEPRESSION: AN OPEN-LABEL EXTENSION TRIAL
• NEURAL CORRELATES OF ANTI-SUICIDAL RESPONSE TO KETAMINE IN TREATMENT RESISTANT BIPOLAR DEPRESSION (DEEPP-STUDY). PILOT PROJECT
• LOW-DOSE ADJUNCTIVE BREXPIPRAZOLE IN THE TREATMENT OF BIPOLAR I AND II DEPRESSION: AN OPEN-LABEL STUDY

View on source registry